NNI-351
![]() | |
Clinical data | |
---|---|
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C24H24FN5OS |
Molar mass | 449.548 g/mol |
3D model (JSmol) | |
| |
|
NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD).[1][2] As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials.[1]
See also
References
- 1 2 http://adisinsight.springer.com/drugs/800029097
- ↑ Froestl W, Muhs A, Pfeifer A (2013). "Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes". J. Alzheimers Dis. 33 (3): 547–658. doi:10.3233/JAD-2012-121537. PMID 23042218.
External links
- NNI-351 - NeuroNascent, Inc
- NNI-351 - AdisInsight
- Methods and pharmaceutical compositions for treating down syndrome (patent)
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.